EPHA4
|
Survival, onset Loss of function increases survival
Mice, zebrafish, patients
Pharmacological inhibition increases survival
Loss of function mutations long survival
|
TDP-43A315T zebrafish
SOD1A4V, SOD1G93A,
SOD1G37R zebrafish
Tg-SOD1G93AEphA+/- mice
Pharmacological targeting in
Tg-SOD1G93A-rat
|
TDP-43, SOD1
|
Van Hoecke et al., 2012
|
EPHA4 |
Extends survival |
Pharmacological targeting in
Tg-SOD1G93A mice |
SOD1 |
Wu et al.,
2017 |
EPHA4 |
Delays onset |
Tg-PFN1G118V mice |
PFN |
Ling et al. 2018 |
CX3CR1 |
Survival |
Patients |
|
Lopez-Lopez et al.,
2014 |
CX3CR1 |
Survival, knockout reduces survival |
TgSOD1G93A Cx3cr1-/-
mice |
SOD1 |
Liu et al., 2019 |
IL6R
|
C variant Asp358Ala
Increased rate of progression
|
Patients
|
|
Wosiski-Kuhn et al., 2019
|
KCNJ11
|
Survival
|
Patients
Rs5219 increased survival in bulbar ALS, patients with T/T survived
longer
|
|
Vidal-Taboada et al., 2018
|
ABCC8
|
Survival
|
Patients
Rs4148646 increased survival in bulbar ALS patients with G/G survived
longer,
Rs4148642
In spinal ALS patients with C/C have increased progression rate
|
|
Vidal-Taboada et al., 2018
|
UNC13A
|
Survival
Regulates neurotransmitter release
|
Patients
Rs12608932 shorter survival
|
|
Diekstra et al., 2012
|